J-M Michot

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8847899/publications.pdf

Version: 2024-02-01

209	10,041	61857 43	38300 95
papers	citations	h-index	g-index

221	221	221	14486
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Immune-related adverse events with immune checkpoint blockade: a comprehensive review. European Journal of Cancer, 2016, 54, 139-148.	1.3	1,687
2	Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Annals of Oncology, 2016, 27, 559-574.	0.6	749
3	Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. Journal of Clinical Oncology, 2016, 34, 3733-3739.	0.8	586
4	Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncology, The, 2018, 19, 649-659.	5.1	450
5	Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. Journal of Hepatology, 2018, 68, 1181-1190.	1.8	372
6	Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. European Respiratory Journal, 2017, 50, 1700050.	3.1	301
7	Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Annals of Oncology, 2020, 31, 961-964.	0.6	280
8	Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncology, 2019, 5, 1310.	3.4	268
9	Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood, 2017, 130, 267-270.	0.6	255
10	Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. European Journal of Cancer, 2018, 91, 21-29.	1.3	222
11	Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood, 2014, 124, 1119-1126.	0.6	208
12	Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematology,the, 2019, 6, e48-e57.	2.2	195
13	Prevalence of immune-related systemic adverse events inÂpatients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. European Journal of Cancer, 2017, 82, 34-44.	1.3	146
14	Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). European Journal of Cancer, 2017, 84, 212-218.	1.3	132
15	Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment. Clinical Microbiology and Infection, 2018, 24, 216-218.	2.8	125
16	Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Annals of Oncology, 2017, 28, 2860-2865.	0.6	115
17	Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death and Disease, 2021, 12, 258.	2.7	113
18	PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013). Blood, 2014, 124, 290-290.	0.6	112

#	Article	IF	Citations
19	Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. Clinical Cancer Research, 2019, 25, 7331-7339.	3.2	110
20	¹⁸F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Antiâ€“Programmed Death 1 Immune Checkpoint Inhibitor. Journal of Nuclear Medicine, 2018, 59, 15-24.	2.8	102
21	Renal toxicities associated with pembrolizumab. CKJ: Clinical Kidney Journal, 2019, 12, 81-88.	1.4	101
22	Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood, 2012, 119, 2228-2233.	0.6	98
23	Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort. Nature Cancer, 2020, 1, 965-975.	5.7	98
24	Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. Translational Lung Cancer Research, 2017, 6, S8-S20.	1.3	97
25	Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?. European Journal of Cancer, 2019, 122, 72-90.	1.3	97
26	Long-Term Survival in Patients Responding to Antiâ€“PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clinical Cancer Research, 2019, 25, 946-956.	3.2	96
27	Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. European Journal of Cancer, 2018, 96, 91-104.	1.3	94
28	Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Reports, 2020, 2, 100170.	2.6	86
29	Antiviral therapy is associated with a better survival in patients with hepatitis C virus and Bâ€cell nonâ€Hodgkin lymphomas, ANRS HCâ€13 lymphoâ€C study. American Journal of Hematology, 2015, 90, 197-203.	2.0	84
30	A randomized and doubleâ€blind controlled trial evaluating the safety and efficacy of rituximab for warm autoâ€immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology, 2017, 92, 23-27.	2.0	84
31	A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica, 2013, 98, 881-887.	1.7	78
32	Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. , 2019, 7, 337.		75
33	Hemolysis and schistocytosis in the emergency department: consider pseudothrombotic microangiopathy related to vitamin B12 deficiency. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 1017-1022.	0.2	70
34	Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood, 2016, 128, 574-583.	0.6	69
35	From hepatitis C virus infection to B-cell lymphoma. Annals of Oncology, 2018, 29, 92-100.	0.6	63
36	Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy. American Journal of Ophthalmology, 2019, 202, 109-117.	1.7	62

#	Article	IF	Citations
37	Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmunity Reviews, 2015, 14, 680-685.	2.5	58
38	Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy. Annals of the Rheumatic Diseases, 2018, 77, 468-470.	0.5	56
39	Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies. European Journal of Cancer, 2017, 81, 135-137.	1.3	55
40	Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody. European Journal of Cancer, 2016, 66, 91-94.	1.3	54
41	Two cases of immune thrombocytopenia associated with pembrolizumab. European Journal of Cancer, 2016, 54, 172-174.	1.3	52
42	Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. European Journal of Cancer, 2018, 101, 160-164.	1.3	52
43	How to manage patients with corticosteroids in oncology in the era of immunotherapy?. European Journal of Cancer, 2020, 141, 239-251.	1.3	52
44	Immunohematologic tolerance of chronic transfusion exchanges with erythrocytapheresis in sickle cell disease. Transfusion, 2015, 55, 357-363.	0.8	50
45	A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. Clinical Cancer Research, 2020, 26, 3145-3153.	3.2	48
46	Impact of aging on immune-related adverse events generated by antiâ€“programmed death (ligand)PD-(L)1 therapies. European Journal of Cancer, 2020, 129, 71-79.	1.3	45
47	Kinetic Profiles and Management of Hepatitis B Virus Reactivation in Patients With Immuneâ€Mediated Inflammatory Diseases. Arthritis Care and Research, 2013, 65, 1504-1514.	1.5	43
48	Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies. Clinical Cancer Research, 2017, 23, 6411-6420.	3.2	43
49	Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1. Annals of the Rheumatic Diseases, 2019, 78, e67-e67.	0.5	40
50	KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure. Blood Advances, 2020, 4, 2617-2622.	2.5	38
51	Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients. , 2020, 8, e001153.		37
52	The 2016â€“2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. European Journal of Cancer, 2020, 130, 39-50.	1.3	37
53	Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients. Blood, 2015, 126, 473-473.	0.6	37
54	Immune-related bone marrow failure following anti-PD1 therapy. European Journal of Cancer, 2017, 80, 1-4.	1.3	36

#	Article	IF	Citations
55	Immune checkpoint inhibitorâ€“associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. European Journal of Cancer, 2021, 158, 208-216.	1.3	33
56	BamlanivimabÂ+ etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies. Annals of Oncology, 2021, 32, 1445-1447.	0.6	33
57	Severe chronic primary neutropenia in adults: report on a series of 108 patients. Blood, 2015, 126, 1643-1650.	0.6	32
58	Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. European Journal of Cancer, 2015, 51, 2386-2395.	1.3	32
59	Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma. European Journal of Cancer, 2018, 91, 136-144.	1.3	32
60	Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies: A Brief Communication. Journal of Immunotherapy, 2018, 41, 84-85.	1.2	30
61	Efficacy of Recombinant Human Interleukin 7 in a Patient With Severe Lymphopenia-Related Progressive Multifocal Leukoencephalopathy. Open Forum Infectious Diseases, 2014, 1, ofu074.	0.4	29
62	Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	29
63	Burkitt and Burkitt-Like Lymphomas: a Systematic Review. Current Oncology Reports, 2020, 22, 33.	1.8	28
64	Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2018-2024.	3.3	27
65	Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review. British Journal of Haematology, 2020, 189, 985-992.	1.2	27
66	Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study. PLoS ONE, 2016, 11, e0162965.	1.1	27
67	Successful Outcome of a Corticodependent Henoch-SchÃ¶nlein Purpura Adult with Rituximab. Case Reports in Medicine, 2014, 2014, 1-4.	0.3	25
68	Challenges and perspectives in the immunotherapy of Hodgkin lymphoma. European Journal of Cancer, 2017, 85, 67-77.	1.3	25
69	Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Long-Term Efficacy from the Phase 1b Keynote-013 Study. Blood, 2016, 128, 1108-1108.	0.6	25
70	Immunotherapy phase I trials in patients Older than 70Âyears with advanced solid tumours. European Journal of Cancer, 2018, 95, 68-74.	1.3	24
71	Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. Lancet Haematology,the, 2020, 7, e649-e659.	2.2	24
72	Infectious complications in patients treated with immune checkpoint inhibitors. European Journal of Cancer, 2020, 141, 137-142.	1.3	24

#	Article	IF	Citations
73	Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit. Annals of Intensive Care, 2020, 10, 143.	2.2	24
74	Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 8-20.e3.	0.2	23
75	PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and Biomarker Assessment. Blood, 2015, 126, 584-584.	0.6	23
76	Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors. Annals of Oncology, 2018, 29, 518-520.	0.6	22
77	Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large Bâ€cell lymphoma, a clinicoâ€pathological series of 25 cases. British Journal of Haematology, 2020, 189, 244-256.	1.2	21
78	Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. Cancer Medicine, 2020, 9, 2643-2652.	1.3	21
79	Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. Blood, 2019, 134, 4079-4079.	0.6	21
80	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAF^{V600} Mutations: A Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology, 2018, 2, 1-9.	1.5	20
81	Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19. Cancer Discovery, 2021, 11, 1336-1344.	7.7	20
82	Psychosis, paraplegia and coma revealing methylenetetrahydrofolate reductase deficiency in a 56-year-old woman. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 963-964.	0.9	19
83	In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. PLoS ONE, 2016, 11, e0156384.	1.1	19
84	A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience. Leukemia and Lymphoma, 2018, 59, 2580-2587.	0.6	18
85	Adenosine deaminase is a useful biomarker to diagnose pleural tuberculosis in low to medium prevalence settings. Diagnostic Microbiology and Infectious Disease, 2016, 84, 215-220.	0.8	16
86	Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. European Journal of Cancer, 2020, 137, 117-126.	1.3	16
87	Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A caseâ€“control study. European Journal of Cancer, 2021, 156, 46-59.	1.3	16
88	Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae. Brain Communications, 2021, 3, fcab220.	1.5	16
89	Ibrutinib-Induced Neutrophilic Dermatosis. American Journal of Dermatopathology, 2018, 40, 198-200.	0.3	15
90	Phase 1b Study of PD-1 Blockade with Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL). Blood, 2015, 126, 3986-3986.	0.6	15

#	Article	IF	Citations
91	A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM). Blood, 2016, 128, 4203-4203.	0.6	15
92	Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	15
93	Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia. American Journal of Hematology, 2015, 90, E131-E132.	2.0	14
94	Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. European Journal of Cancer, 2018, 92, 1-10.	1.3	14
95	Severe COVID-19 in patients with hematological cancers presenting with viremia. Annals of Oncology, 2021, 32, 1297-1300.	0.6	14
96	Belantamab Mafotodin-Induced Epithelial Keratopathy Masquerading Myopic Surgery. Ophthalmology, 2020, 127, 1626.	2.5	13
97	Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma. Blood, 2021, 138, 2494-2494.	0.6	13
98	Patterns of progression in patients treated for immuno-oncology antibodies combination. Cancer Immunology, Immunotherapy, 2021, 70, 221-232.	2.0	12
99	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. Oncotarget, 2018, 9, 9741-9750.	0.8	12
100	Cusatuzumab for treatment of CD70â€positive relapsed or refractory cutaneous Tâ€cell lymphoma. Cancer, 2022, 128, 1004-1014.	2.0	12
101	Severe gastro-intestinal angiodysplasia in context of Heyde's syndrome durably cured after aortic valve replacement. Presse Medicale, 2012, 41, 763-766.	0.8	10
102	Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience. European Journal of Cancer, 2018, 98, 17-22.	1.3	10
103	New insights on IgA vasculitis with underlying solid tumor: a nationwide French study of 30 patients. Clinical Rheumatology, 2021, 40, 1933-1940.	1.0	10
104	Updates in the Treatment of Peripheral T-Cell Lymphomas. Journal of Experimental Pharmacology, 2021, Volume 13, 577-591.	1.5	10
105	Antiâ€“programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study. European Journal of Cancer, 2022, 160, 134-139.	1.3	10
106	Post-shingles granulomatous dermatosis related to anti-programmed cell death 1. Immunotherapy, 2019, 11, 591-598.	1.0	9
107	Pirtobrutinib shows evidence to inaugurate a third generation of BTK inhibitors. Lancet, The, 2021, 397, 855-857.	6.3	9
108	Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study. Blood, 2015, 126, 4263-4263.	0.6	9

#	Article	IF	Citations
109	CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy. Cancers, 2021, 13, 5487.	1.7	9
110	Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy. European Journal of Cancer, 2017, 75, 308-309.	1.3	8
111	Repeated courses of lowâ€dose 2ÂÃ—Â2ÂGy radiation therapy in patients with indolent Bâ€cell nonâ€Hodgkin lymphomas. Cancer Medicine, 2020, 9, 3725-3732.	1.3	8
112	Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial. Blood, 2016, 128, 619-619.	0.6	8
113	Very prolonged liposomal amphotericin B use leading to a lysosomal storage disease. International Journal of Antimicrobial Agents, 2014, 43, 566-569.	1.1	7
114	Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?. British Journal of Cancer, 2018, 119, 937-939.	2.9	7
115	Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.. Journal of Clinical Oncology, 2016, 34, 8006-8006.	0.8	7
116	Haemophagocytic histiocyte in a peripheral blood film. British Journal of Haematology, 2014, 165, 163-163.	1.2	6
117	THU0628â€...IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES. BIG DATA ANALYSIS OF 13,051 CASES (IMMUNOCANCER INTERNATIONAL REGISTRY). , 2019, , .		6
118	Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e373-e380.	0.2	6
119	Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrinÂalpha4 therapy. European Journal of Cancer, 2021, 145, 230-233.	1.3	6
120	Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. European Journal of Cancer, 2021, 157, 383-390.	1.3	6
121	Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell Lymphoma in a Phase 1/2 Clinical Trial. Blood, 2018, 132, 1627-1627.	0.6	6
122	Incidence of immune related adverse events in patients 70 years old treated with anti-PD-(L)1 therapy. Annals of Oncology, 2018, 29, viii428-viii429.	0.6	5
123	Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1. Annals of Oncology, 2018, 29, viii405.	0.6	5
124	Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study. Blood, 2021, 138, 3574-3574.	0.6	5
125	Phase I/II Study of MAK683 in Patients with Advanced Malignancies, Including Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 1422-1422.	0.6	5
126	Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial. Blood Advances, 2022, 6, 6169-6179.	2.5	5

#	Article	IF	Citations
127	Large granular lymphocyte leukemia and lymphomatoid granulomatosis in the same patient: fortuitous association?. Leukemia and Lymphoma, 2013, 54, 432-434.	0.6	4
128	Long-term impact of immunotherapy on quality of life of surviving patients: A multi-dimensional descriptive clinical study. European Journal of Cancer, 2021, 148, 211-214.	1.3	4
129	Avadomide (CC-122), a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Blood, 2018, 132, 449-449.	0.6	4
130	Clinical efficacy of HER3 partners' inhibitors in ERBB3 mutated cancer patients. Annals of Oncology, 2016, 27, vi38.	0.6	3
131	Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. Investigational New Drugs, 2018, 36, 62-74.	1.2	3
132	Highâ€dose cyclophosphamide for hardâ€toâ€treat patients with relapsed or refractory Bâ€cell nonâ€Hodgkin's lymphoma, a phase II result. European Journal of Haematology, 2020, 104, 281-290.	1.1	3
133	16O Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL). Annals of Oncology, 2020, 31, S5.	0.6	3
134	Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study. Blood, 2018, 132, 4191-4191.	0.6	3
135	BEAM or BeEAM High-Dose Chemotherapy Followed By ASCT: A Single Center Comparative Analysis of Toxicity. Blood, 2016, 128, 4648-4648.	0.6	3
136	BRAF V600E Targetable Mutation in Relapsed/Refractory Multiple Myeloma (R/R MM) Patients: A High Incidence in R/R MM Detected Using Cell Sorting Screening. Blood, 2016, 128, 5638-5638.	0.6	3
137	Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE Antibody ARGX-110.. Journal of Clinical Oncology, 2016, 34, 7556-7556.	0.8	3
138	An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013. , 2015, 3, .		2
139	Reply to: â€œIncidence of grade 3â€“4 liver injury under immune checkpoints inhibitors: A retrospective studyâ€• Journal of Hepatology, 2018, 69, 1397-1398.	1.8	2
140	CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL). Annals of Oncology, 2018, 29, iii9.	0.6	2
141	Reply to: â€œImmune-related hepatitis with immunotherapy: Are corticosteroids always needed?â€• Journal of Hepatology, 2018, 69, 550-551.	1.8	2
142	Reply to: â€œAcute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?â€• Journal of Hepatology, 2019, 70, 566-567.	1.8	2
143	Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large <scp>B</scp>â€cell lymphoma: Results of <scp>LNHâ€EP1</scp> study. American Journal of Hematology, 2021, 96, E376-E379.	2.0	2
144	Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?. Annals of Oncology, 2021, 32, 936-937.	0.6	2

#	Article	IF	Citations
145	Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic. Cancer Cell, 2021, 39, 1039-1041.	7.7	2
146	Abstract CT029: The effect of tazemetostat on CYP3A-mediated metabolism of midazolam in patients with solid tumors. Cancer Research, 2016, 76, CT029-CT029.	0.4	2
147	Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma. Blood, 2020, 136, 41-42.	0.6	2
148	Auto-Immune Origin of B Cells from HCV-Associated Lymphoma. Blood, 2015, 126, 1464-1464.	0.6	2
149	Evaluation of PFS ratio in patients with cancer enrolled in early-phase clinical trials: A single center, retrospective analysis.. Journal of Clinical Oncology, 2017, 35, e14025-e14025.	0.8	2
150	Notch inhibitors induce diarrhea, hypercrinia and secretory cell metaplasia in the human colon. EXCLI Journal, 2021, 20, 819-827.	0.5	2
151	Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs. European Journal of Cancer, 2022, 167, 42-53.	1.3	2
152	Distinct efficacy of pegylated-interferon Î±2a and Î±2b during treatment of essential thrombocythemia. International Journal of Hematology, 2013, 97, 438-439.	0.7	1
153	Pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS): Phase 2 KEYNOTE-170 study. Annals of Oncology, 2016, 27, vi325.	0.6	1
154	Identification of new prognostic factors in phase I patients treated by immunotherapy. Annals of Oncology, 2016, 27, vi124.	0.6	1
155	KEYNOTE-170: Phase 2 study of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS). Annals of Oncology, 2016, 27, viii15.	0.6	1
156	P3.02c-032 Interstitial Pneumonitis Associated with Immune Checkpoint Inhibitors Treatment in Cancer Patients. Journal of Thoracic Oncology, 2017, 12, S1292-S1293.	0.5	1
157	Prognostic factors and outcome of patients with hematological malignancies in phase I trials. Anti-Cancer Drugs, 2017, 28, 540-545.	0.7	1
158	Sarcoidosis-like reaction mimics progression in patients treated with immune checkpoint inhibitors. Annals of Oncology, 2019, 30, v529-v530.	0.6	1
159	MA05.11 Safety and Efficacy of Nintedanib in Combination with Pembrolizumab in Patients with Refractory/Relapsing Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2019, 14, S268.	0.5	1
160	527O CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study. Annals of Oncology, 2020, 31, S463-S464.	0.6	1
161	Attenuated cytarabine, etoposide, dexamethasone plus rituximab (Râ€Miniâ€CYVE) regimen for patients with relapsed or refractory Bâ€cell nonâ€“Hodgkinâ€™s lymphoma not eligible for intensive chemotherapy. European Journal of Haematology, 2021, 106, 574-583.	1.1	1
162	22P Toxicity profile of immune and non-immune therapies in phase I/II trials: A comprehensive longitudinal analysis. Annals of Oncology, 2021, 32, S10.	0.6	1

#	Article	IF	Citations
163	Non-Effectiveness of Using RICE Post RDHAP or RDHAP Post RICE after Failure of First Line Salvage Therapy in DLBCL Patients Who Are Eligible for ASCT. Blood, 2018, 132, 4226-4226.	0.6	1
164	A Multi-Centre Randomized and Double-Blind Controlled Trial of Rituximab for Warm Autoimune Hemolytic Anemia in Adults. Blood, 2015, 126, 3338-3338.	0.6	1
165	A Phase 1B Study of CC-122 in Combination with Obinutuzumab (GA101) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin Lymphoma. Blood, 2016, 128, 4199-4199.	0.6	1
166	Molecular Profiling Feasibility on Cell-Free Tumoral DNA in Relapse/Refractory (R/R) Multiple Myeloma (MM) Patients Screened for Phase I Trials. Blood, 2021, 138, 3763-3763.	0.6	1
167	Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma. Haematologica, 2022, 107, 1928-1932.	1.7	1
168	Late Recurrent Testicular Seminoma: Histological Evidence Is Required. Oncology Research and Treatment, 2015, 38, 286-288.	0.8	0
169	Outcome of patients with relapsed/refractory lymphoma in a large cohort inside a phase 1 clinic department. Annals of Oncology, 2015, 26, ii16.	0.6	0
170	Patients with metastatic prostate cancer enrolled in phase 1 trials: Outcomes and molecular alterations. Annals of Oncology, 2016, 27, vi130.	0.6	0
171	Local treatment for scleritis secondary to Wiskott-Aldrich syndrome. Journal Francais D'Ophtalmologie, 2016, 39, e63-e64.	0.2	0
172	Gastrointestinal Immune Related Adverse Events Associated with Programmed-Death 1 Blockade. Gastroenterology, 2017, 152, S194.	0.6	0
173	Long-Term Outcomes in Patients With Solitary Bone Plasmacytoma Treated With Definitive Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, E426-E427.	0.4	0
174	Hematological adverse events related to the immune system with immune checkpoint inhibitors, a comprehensive review as a basis for clinical guidelines. Hematologie, 2018, 24, 183-193.	0.0	0
175	Safety assessment of anti-PD(L)1 rechallenge after immune-related adverse events. Annals of Oncology, 2018, 29, viii427-viii428.	0.6	0
176	Molecular screening in advanced cancer patients with head and neck cancers: A retrospective analysis of the MOSCATO-01 trial. Annals of Oncology, 2018, 29, viii378-viii379.	0.6	0
177	Precision medicine for patients with rare cancers: An effective strategy within the prospective MOSCATO trial. Annals of Oncology, 2018, 29, viii667.	0.6	0
178	Reply to: â€œMortality due to immunotherapy related hepatitisâ€• Journal of Hepatology, 2018, 69, 978-979.	1.8	0
179	Are epigenetic therapies modifying sensitivity to conventional chemotherapy?. Annals of Oncology, 2019, 30, v188-v189.	0.6	0
180	Clinical significance of immune-related creatine phosphokinase increase associated with anti PD1/PD-L1 immunotherapies. Annals of Oncology, 2019, 30, v526.	0.6	0

#	Article	IF	Citations
181	Safety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes?. Annals of Oncology, 2019, 30, i5.	0.6	0
182	1694P Discovery of circulating biomarkers in COVID-19 patients undergoing anti-IL6R immunotherapy. Annals of Oncology, 2020, 31, S1000-S1001.	0.6	0
183	47P Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs. Annals of Oncology, 2020, 31, S1435.	0.6	0
184	1050P Does immunotherapy impact the outcomes of future anti-tumour therapies?. Annals of Oncology, 2020, 31, S718-S719.	0.6	0
185	66P High incidence of TP53 and epigenetic modifying oncogene mutations in a large cohort of patients enrolled in phase I clinical trials for R/R DLBCL. Annals of Oncology, 2020, 31, S1237.	0.6	0
186	24P Is molecular characterization useful for targeted therapy orientation in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) included in early phase clinical trials?. Annals of Oncology, 2020, 31, S1224.	0.6	0
187	Letter responds to the comment in â€˜immune thrombocytopenia of haematological immune-related adverse events in cancer immunotherapy: Most and mightyâ€™. European Journal of Cancer, 2020, 134, 60-61.	1.3	0
188	8MO CC-90010, a reversible, potent oral bromodomain and extraterminal inhibitor (BETi) in patients (pts) with advanced solid tumours (aSTs) and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Longer follow-up from parts A & B and first reporting of part C of a phase I study. Annals of Oncology, 2021, 32, S5.	0.6	0
189	9P Predictive factors and profiles of tumour response to epigenetic drugs in phase I trials. Annals of Oncology, 2021, 32, S5.	0.6	0
190	Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?. Human Vaccines and Immunotherapeutics, 2021, 17, 3502-3510.	1.4	0
191	1773P Anti-PD1-induced acute interstitial pneumonitis is characterized by alveolar infiltration of PD-1+CD38+TIGIT+ cytotoxic effector CD8+ T cells and CD206+ inflammatory macrophages. Annals of Oncology, 2021, 32, S1216.	0.6	0
192	1617P Sustained cancer clinical trial activity during the COVID-19 pandemic. Annals of Oncology, 2021, 32, S1151.	0.6	0
193	1639P Impact of COVID-19 on ongoing oncological and hematological treatment strategy. Annals of Oncology, 2021, 32, S1159.	0.6	0
194	Histological Characteristics Of Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. Results Of The French Lympho-C ANRS HC-13 Multicentric Study Of 133 Patients. Blood, 2013, 122, 3005-3005.	0.6	0
195	A Simple Scoring System for Identifying Relapsed/Refractory Lymphoma Patients Prematurely Withdrawn from Phase I Trials: The Gustave Roussy Experience. Blood, 2014, 124, 1759-1759.	0.6	0
196	Prognostic Factors and Outcome of Patients with Hematological Malignancies in Phase I Trials: The Gustave Roussy Scoring System. Blood, 2014, 124, 3504-3504.	0.6	0
197	Concurrent Radiation and ESHAP Regimen in Localized Extranodal NK/T-Cell Lymphoma Nasal Type, Phase II French Study. Blood, 2014, 124, 1707-1707.	0.6	0
198	Abstract CT031: The effect of food on the pharmacokinetics (pk) of tazemetostat in patients with cancer. , 2016, , .		0

#	Article	IF	Citations
199	Repetitive Low-Dose Radiation Therapies As an Alternative Option for Indolent Non-Hodgkin Lymphoma. Blood, 2016, 128, 1784-1784.	0.6	0
200	Abstract CT141: Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial). , 2018, , .		0
201	Immunological Cytopenias Induced By Anti-Programmed Cell Death (ligand) 1 Antibodies. Blood, 2018, 132, 2412-2412.	0.6	0
202	Outcomes of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Included in Phase I Clinical Trials. Blood, 2018, 132, 2992-2992.	0.6	0
203	Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2018, 132, 2001-2001.	0.6	0
204	Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood, 2018, 132, 4110-4110.	0.6	0
205	Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas. Blood, 2019, 134, 1496-1496.	0.6	0
206	Thromboembolic risk assessment in patients receiving combination of anti-angiogenic plus anti-PD1 or anti-PD-L1: A descriptive study. Annals of Oncology, 2019, 30, xi18.	0.6	0
207	High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 10-11.	0.6	0
208	Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?. Blood, 2020, 136, 18-19.	0.6	0
209	193P Safety and efficacy of immmunotherapy rechallenge following a previous immune-induced interstitial lung disease. Annals of Oncology, 2022, 33, S118-S119.	0.6	0